Lurex Bio

Cell & Gene Therapy · Biotechnology

Overview

LurexBio is developing a non genetic, non viral recognition engineering platform to address an important component of tumor immune evasion in immune cold cancers.

Funding and backers

Total raised
$150k
1 round on record
Latest round
$150k
Venture round · Jan 2026 · 9 mo ago
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 22 Raised a round Venture round $150k · SEC Form D 2025 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jan 2026 $150k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity LUREX BIO, INC SEC Form D
Founders and leadersfrom filings, registers and the company's site
George SensExecutive OfficerSEC Form D
Mark ShumateExecutive Officer, DirectorSEC Form D
Horace Lanier IIIExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
UCL Technology Fund
backs ViaNautis, Spur Therapeutics
Claris Ventures
backs ALKemist Bio, Haptena Therapeutics
NEA
backs Code Biotherapeutics
Albion
backs Spur Therapeutics
BGF
backs ViaNautis
ARCH Venture Partners
backs Qihan Biotech
Similar startupsby what they do, their industry and backers
ViaNautis
ViaNautis is transforming cell and gene therapy with polyNaut®, a versatile, non-viral, targeted polymer-based nanovesicles delivery system…
Qihan BiotechFounded 2017
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome…
Code Biotherapeutics51-200 employees
Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to…
SyncromuneVenture round $144.8M · 23 mo ago · 51-200 employees
Syncromune® is developing SYNC-T®, a platform immunotherapy designed to synchronize the location of 3 key components needed to educate the…
ALKemist BioVenture round $7.5M · 2 yr ago · 11-50 employees
ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune…
ReforgeneFounded 2019 · 2 roles
Reforgene is a Chinese biotechnology company developing cell and gene therapies. Its research covers ex vivo and in vivo gene editing, gene…

Financials

Total raised
$150k
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 $150k Details

People

George Sens
Executive Officer
SEC Form D
Mark Shumate
Executive Officer, Director
SEC Form D
Horace Lanier III
Executive Officer, Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Fort Lauderdale United States
HQ
Our Location
501 East Las Olas Blvd., Suite 300, Fort Lauderdale, FL 33301
company site